

Prepared for Presentation at  
**NATURAL RADIATION ENVIRONMENT V**  
Salzburg, Austria  
September 22-28, 1991

**<sup>222</sup>Rn Alpha Dose to Organs Other than Lung**  
Naomi H. Harley, Edith S. Robbins  
New York University School of Medicine  
550 First Avenue, New York, NY 10016

**DISCLAIMER**

This report was prepared as an account of work sponsored by an agency of the United States Government. Neither the United States Government nor any agency thereof, nor any of their employees, makes any warranty, express or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States Government or any agency thereof. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States Government or any agency thereof.

**MASTER**

# <sup>222</sup>Rn Alpha Dose to Organs Other than Lung

Naomi H. Harley, Edith S. Robbins

New York University School of Medicine

550 First Avenue, New York, NY 10016

## ABSTRACT

The alpha dose to cells in tissues or organs other than the lung has been calculated using the solubility coefficients for <sup>222</sup>Rn measured in human tissue. The annual alpha dose equivalent from <sup>222</sup>Rn and decay products in most tissues is a maximum of 30% of the annual average natural background dose equivalent (1 mSv) for external and internally deposited nuclides (not including the dose equivalent for <sup>222</sup>Rn decay products to cells in bronchial airways). The dose to the small population of lymphocytes located in or under the bronchial epithelium is a special case and their annual dose equivalent is essentially the same as that to basal cells in bronchial epithelium (200 mSv) for continuous exposure to 200 Bq m<sup>-3</sup>. The significance of this dose is uncertain because the only excess cancer observed in follow up studies of underground miners with high <sup>222</sup>Rn exposure is bronchogenic carcinoma.

## $^{222}\text{Rn}$ Alpha Dose in Organs Other than Lung

Naomi H. Harley, Edith S. Robbins

New York University School of Medicine

550 First Avenue, New York, NY 10016

### INTRODUCTION

Harley and Pasternack<sup>(1)</sup> calculated the dose to cells on bone surfaces and in hemopoietic bone marrow for normal marrow and fatty bone marrow from  $^{222}\text{Rn}$  and its decay products. These calculations used outdoor  $^{222}\text{Rn}$  concentration and the alpha dose to these cells was considered negligible compared to the dose to cells in the bronchial airways from this source.

It was well known at the time that certain organs contain substantial amounts of adipose tissue. Bone marrow in the child, for example, contains almost no fat because the marrow is active and is producing blood cells. In the adult the active hemopoietic fraction of bone marrow space is reduced markedly with 1.5 kg being active and 1.5 kg being fatty marrow.

Other organs in the body also contain or are surrounded by notable amounts of adipose tissue, namely, the female breast, subcutaneous fat and the omentum. Some organs are partially enveloped in significant amounts of fat such as the eye, kidney and salivary glands. It has been well known for many years that

noble gases are more soluble in fats and oils than in aqueous media by about a factor of  $10^{(2)}$ .

The increased solubility of  $^{222}\text{Rn}$  in adipose tissue might be of some dosimetric consequence in situations where indoor  $^{222}\text{Rn}$  concentrations are high. Henshaw et al.<sup>(3)</sup> speculated that this  $^{222}\text{Rn}$  solubility may be responsible for cancers other than lung cancer and in particular leukemia. For this reason we have recalculated the alpha dose from  $^{222}\text{Rn}$  and decay products to various tissues in the body and estimated the projected cancer risk for continuous indoor exposure.

It should be noted, as a background for these risk estimates, that follow up studies of underground miners exposed to  $^{222}\text{Rn}$  concentrations of up to thousands of  $\text{Bq m}^{-3}$  for many years have shown no cancer other than lung cancer above that expected normally<sup>(4)</sup>. The one exception to this is excess skin cancer (basal cell carcinoma) reported in underground uranium miners in Czechoslovakia, however, this is usually attributed to the airborne arsenic levels in this one group of mines<sup>(5)</sup>.

#### Dose Calculations

The solubility of  $^{222}\text{Rn}$  in human tissues is obtained from experimental measurements by Harley et al<sup>(6)</sup>. He remained in a  $^{222}\text{Rn}$  test chamber on 2 occasions, for 8 1/2 and 7 hours

respectively. The chamber  $^{222}\text{Rn}$  concentration was measured during these two studies at 26 and 22  $\text{kBq m}^{-3}$  respectively. Breath samples were measured for  $^{222}\text{Rn}$  sequentially following exposure for up to about 75 hours. Five separate compartments could be fit to the  $^{222}\text{Rn}$  exhalation data. The calculated volume of these compartments indicated that they corresponded to the lung, the blood, the interstitial fluid, intracellular fluid and fatty tissue. The integrated amount of  $^{222}\text{Rn}$  in the last four compartments permitted the Ostwald coefficients to be determined ( $^{222}\text{Rn}$  concentration  $\text{kg}^{-1}$  tissue per  $\text{Bq m}^{-3}$  in air). The agreement between Ostwald coefficients for the 2 exposure times supported the conclusion that a steady state had been attained. The calculated Ostwald coefficients are shown in Table 1.

These coefficients are the only reported human data for  $^{222}\text{Rn}$  solubility. Studies with rats sacrificed after exposure were performed by Nussbaum and Hursh<sup>(7)</sup>. They found an Ostwald coefficient for soft tissues in the rat in agreement with that in Table 1, but 6 times higher for the fat (omentum only) than for the total human fatty tissue (5.2 vs. 0.8). The data for omental tissue agrees with the in vitro measurements of  $^{222}\text{Rn}$  solubility in human extracted fat (5.2 vs. 6.2)<sup>(2)</sup>. The reason for the lack of agreement of the Ostwald coefficient between human adipose tissue and rat omentum is not known but the human solubility data are necessarily used for all calculations.

## DOSE TO BONE MARROW, BONE SURFACE CELLS AND BREAST

The calculated doses for body tissues and for cells in active bone marrow and in fatty bone marrow are also shown in Table 1. The doses in  $\text{mSv y}^{-1}$  are given for average indoor  $^{222}\text{Rn}$  concentrations of  $40 \text{ Bq m}^{-3}$  and for a concentration of  $200 \text{ Bq m}^{-3}$ , the value that many countries use as a guideline for home remediation. For comparison, a dose equivalent exposure rate of  $1 \text{ mSv y}^{-1}$  from external and internal emitters is essentially the average total background exposure for most countries<sup>(8)</sup>. This dose equivalent value of  $1 \text{ mSv y}^{-1}$  for all organs in the body does not include the alpha dose to the bronchial airways from  $^{222}\text{Rn}$  decay products which is always considerably higher (20 to  $40 \text{ mSv y}^{-1}$ ) for average indoor  $^{222}\text{Rn}$  concentrations of 20 to  $40 \text{ Bq m}^{-3}$ .

The dose values reported have been calculated using conventional uniform tissue dosimetry for blood and soft tissue, using dosimetry developed from measured stopping power data for cells in bronchial airways and alveolar tissue<sup>(9)</sup> and using the dosimetry developed for cells on bone surfaces and in marrow<sup>(1)</sup>.

It can be seen that at  $200 \text{ Bq m}^{-3}$  the dose to cells in bone marrow that are the presumed stem cells for leukemia induction from  $^{222}\text{Rn}$  and decay products is about 25% of the average annual

external exposure rate of  $1 \text{ mSv y}^{-1}$ . The dose to fatty tissue is  $0.3 \text{ mSv y}^{-1}$  and, if it is assumed that an organ such as the female breast is composed of mostly fatty tissue (about 80% adipose tissue), this also corresponds to the breast dose.

#### SKIN DOSE

The dose to basal cells in skin at a depth of 50  $\mu\text{m}$  from deposited  $^{222}\text{Rn}$  decay products was calculated by Sevcova et al.<sup>(5)</sup> for underground miners in Czechoslovakian uranium mines. The skin dose from  $^{222}\text{Rn}$  exposure at environmental conditions was calculated by Harley et al.<sup>(10)</sup> and is recalculated in the present work. The alpha dose from deposited decay products is only significant for exposed skin. The alpha particle range from  $^{218}\text{Po}$  and  $^{214}\text{Po}$  is not sufficient (47 and 70  $\mu\text{m}$ ) to penetrate clothing. Sevcova et al.<sup>(5)</sup> indicated that the excess basal cell carcinoma observed in these miners was on the forehead and cheek. Melanoma has not been observed in excess in any of the follow up mining studies.

The skin dose is highly dependent upon the deposition velocity chosen for the decay products. In the measurements reported by Sevcova et al.<sup>(5)</sup> a deposition velocity of  $3 \text{ cm min}^{-1}$  can be estimated. George and Knutson<sup>(11)</sup> measured a deposition velocity of  $0.045 \text{ cm min}^{-1}$  for stationary detectors in a  $^{222}\text{Rn}$  test chamber. If a deposition velocity of  $0.045$  to  $1 \text{ cm min}^{-1}$

(stationary to active movement) is assumed for persons in a home environment then the alpha dose to basal cells located 50  $\mu\text{m}$  below the epithelial surface is 10 to 200  $\text{mSv y}^{-1}$  for a  $^{222}\text{Rn}$  concentration of 200  $\text{Bq m}^{-3}$ . This is comparable to the dose to cell nuclei in bronchial airways for continuous exposure to 200  $\text{Bq m}^{-3}$ .

#### DOSE TO T LYMPHOCYTES

There is a report of possible association of mutation frequency in peripheral T lymphocytes and indoor  $^{222}\text{Rn}$  exposure<sup>(12)</sup>. Lymphocytes can be irradiated in several geometries by  $^{222}\text{Rn}$  and decay products. They can be irradiated in the following situations.

1. In blood by  $^{222}\text{Rn}$  and decay products soluble in blood.
2. In alveolar capillaries by alpha emitters on the alveolar surfaces of the lung.
3. In intraepithelial tissue while white cells are within bronchial epithelium by alpha emitters deposited on the bronchial airways.
4. In special areas of connective tissue beneath the bronchial airways (bronchus associated lymphoid tissue).
5. Within the connective tissue of interalveolar septa.
6. Within lymphoid vessels accompanying the airways and lung vasculature.

4. In special areas of connective tissue beneath the bronchial airways (bronchus associated lymphoid tissue).
5. Within the connective tissue of interalveolar septa.
6. Within lymphoid vessels accompanying the airways and lung vasculature.
7. Within the lung pleura, within the connective tissue or lymphatic vessels.

The fraction of T lymphocytes in these various locations is not well known and their lifespan can be large, ranging up to 40 years. Fig. 1 shows an electron micrograph of a human bronchus indicating the typical location of basal and mucous cell nuclei and an intraepithelial lymphocyte. Fig. 2 illustrates the relationship between the airspace and the bloodspace in the human lung parenchyma.

The annual dose to a T lymphocyte from irradiation in these various locations has been calculated and is given in Table 1. The dose equivalent can range from 0.2 to 200 mSv  $y^{-1}$  for continuous exposure to 200 Bq  $m^{-3}$ .

#### RISK ESTIMATES

The International Commission on Radiation Protection has updated the lifetime risk of various types of cancer<sup>(13)</sup>. The risk of leukemia and breast cancer are 0.005 and 0.002  $Sv^{-1}$  respectively. Assuming a lifetime (70 year) exposure at an

per million persons in the U.S., for example, for leukemia and female breast cancer.

The major risk from  $^{222}\text{Rn}$  decay products results from irradiation of basal and mucous cell nuclei in bronchial epithelium<sup>(8)</sup>. The annual dose equivalent to these cell nuclei for an indoor concentration of  $200 \text{ Bq m}^{-3}$  is about 200 mSv.

The same magnitude alpha dose equivalent is delivered to lymphocytes in or under bronchial epithelium as to basal cell nuclei. Lymphocytes in bronchial epithelium are a small fraction of the lymphocyte population. Their abundance is a few percent of that of basal cells in bronchial epithelium<sup>(14)</sup>. Jeffrey et al.<sup>(15)</sup> measured the fraction of these intraepithelial migratory cells that are lymphocytes as 60 and 90% of the total. Most of the lymphocytes present in bronchial epithelium are T lymphocytes<sup>(16)</sup>. Both T and B lymphocytes have the potential to be stem cells for lymphoma although the consequence of their irradiation and possible mutation is unknown. Bronchial epithelial lymphocytes may be in the process of exiting the body since they have been recovered in bronchial lavage<sup>(16)</sup>. Bosanko et al<sup>(17)</sup> reported that although rare, primary pulmonary lymphoma does occur. The fact remains that follow up studies of underground miners document only excess lung cancer.

Acknowledgement. The authors would like to thank Dr. John H. Harley for many helpful suggestions in the preparation of this manuscript. This work was supported by U.S. DOE Contracts DE AC02 EV10374 (NHH) and DE FG02 88ER60656 (ESR) and in part for the first author by Center Grants from NIEHS ES00260 and NCI CA13343. All support is gratefully acknowledged.

## TABLE TITLES

Table 1. Ostwald solubility coefficients for  $^{222}\text{Rn}$  in human tissues and alpha dose equivalents in selected organs.

## FIGURE CAPTIONS

Figure 1. Electron micrograph of the human bronchial mucosa from a generation 5 airway. Typical basal (B), mucous or goblet (M) and an intermediate or indeterminate (X) cell types are indicated. The latter category is heterogeneous and includes cells of ambiguous morphology as well as moribund cells. Also present is an intraepithelial lymphocyte (L); a blood vessel of the lamina propria is identified with a C in the lumen. Magnification 2500X.

Figure 2. Electron micrograph of a human lung interalveolar septum illustrating the distance from airspace (A) to bloodspace. The capillary contains red blood cells (R). An arrow indicates the attenuated cytoplasm of the type I pneumocyte layer which forms the air-tissue interface. The very thin surfactant layer has been lost (as is typical in specimens fixed by immersion). The connective tissue core of the septum contains abundant elastic fibers one of which is designated (E) as well as collagen fibers and the processes of cells but in the region of capillary approximation of the epithelium the connective tissue space is reduced to two apparently fused basal laminae (of the epithelium and endothelium). As measured here the minimum distance to the capillary lumen is 0.5  $\mu\text{m}$ . Magnification 12,000X.

## REFERENCES

1. Harley, N.H. and Pasternack, B.S., The beta dose to critical human tumor sites from krypton-85. *Health Phys.* 33, 567 (1977)
2. Nussbaum, E. and Hursh, J.B., Radon solubility in fatty acids and triglycerides. *Phys. Chem* 62, 81 (1958)
3. Henshaw, D.L., Eatough, J.P. and Richardson, R.B., Radon as a causative factor in induction of myeloid leukemia and other cancers. *Lancet* 335, 1008 (1990)
4. NCRP, Evaluation of Occupational and Environmental Exposures to Radon and Radon Daughters in the United States. National Council on Radiation Protection and Measurements Report No. 78. NCRP, Bethesda, MD. (1984)
5. Sevcova, M., Sevc, J. and Thomas, J., Alpha irradiation of the skin and the possibility of late effects. *Health Phys.* 35, 803 (1978)
6. Harley, J.H., Jetter, E. and Nelson, N., Elimination of Rn from the body. USAEC Report HASL-32. USAEC, New York. (1953)
7. Nussbaum, E. and Hursh, J., Radon solubility in rat tissues. *Science.* 125, 552 (1957)

8. NCRP, Exposure to the Population in the United States and Canada from Natural Background Radiation. National Council on Radiation Protection and Measurements Report No. 94. NCRP, Bethesda, MD. (1987)
9. Harley, N.H. and Pasternack, B.S., Alpha absorption measurements applied to lung dose from radon daughters. Health Physics 23, 771 (1972)
10. Harley, N.H., Kolber, A.B., Shore, R.E., Albert, R.E., Altman, S.M. and Pasternack, B.S., The skin dose and response for the head and neck in patients irradiated with x-ray for tinea capitis: Implications for environmental radioactivity. In: Epidemiology Applied to Health Physics, Sixteenth Midyear Topical Meeting of the Health Physics Society. CONF-830101. (ed) HPS, Albuquerque, NM. (1983)
11. George, A.C., Knutson, E.O. and Tu, K.W., Radon Daughter Plateout- I. Measurements. Health Phys. 45, 439-444 (1983)
12. Bridges, B.A., Cole, J., Arlett, C.F., Green, M.H.L., Waugh, A.P.W., Beare, D., Henshaw, D.L. and Last, R.D., Possible association between mutant frequency in peripheral lymphocytes and domestic radon concentrations. Lancet. 337, 1187-89 (1991)

13. ICRP, 1990 Recommendations of the International Commission on Radiological Protection. ICRP Publication 60. Annals of the ICRP 21, No. 1-3. Pergamon Press, Oxford. (1991)
14. Robbins, E.S., Meyers, O.A. and Harley, N.H., Quantification of the nuclei of human bronchial epithelial cells from electron micrographs for radon risk analysis. In: Proceedings of the XIIth International Congress for Electron Microscopy. (ed) San Francisco Press, San Francisco. (1990)
15. Jeffrey, P.K., Wardlaw, F.C., Nelson, J.V. Kay, A.B., Bronchial biopsies in asthma. Am. Rev. Resp. Dis. 140, 1745-1753 (1989)
16. Fournier, M., Lebargy, F., Ladurie, F.L., Normand, E. and Pariente, R., Intraepithelial T-lymphocyte subsets in the airways of normal subjects and of patients with chronic bronchitis. Am. Rev. Respir. Dis. 140, 737-42 (1989)
17. Bosanko, C.M., Korobkin, M., Fantone, J.C., Rubin, S.B., Lynch, J.P., Lobar primary pulmonary lymphoma: CT findings. J. Comp. Assisted Tomography 15, 679-682 (1991).

Site	Ostwald Coefficient Bq kg <sup>-1</sup> tissue per Bq m <sup>-3</sup> air	Alpha Dose Equivalent <sup>(1)</sup>	
		40 Bq m <sup>-3</sup> mSv y <sup>-1</sup>	200 Bq m <sup>-3</sup> mSv y <sup>-1</sup>
Blood	5.6 x 10 <sup>-4</sup>	0.04	0.22
Soft Tissue	3.2 x 10 <sup>-4</sup>	0.02	0.12
Fatty Tissue	8.1 x 10 <sup>-4</sup>	0.06	0.31
Normal Marrow	3.2 x 10 <sup>-4</sup>	0.021	0.10
Fatty Marrow	8.1 x 10 <sup>-4</sup>	0.053	0.26
Bone Surfaces (normal marrow)	3.2 x 10 <sup>-4</sup>	0.02	0.08
Bone Surfaces (fatty marrow)	8.1 x 10 <sup>-4</sup>	0.04	0.20
Skin (exposed) <sup>2</sup>	NA <sup>3</sup>	2-40	10-200
T lymphocytes			
Circulating	5.0x 10 <sup>-4</sup>	0.04	0.2
in B.E. <sup>4</sup>	NA <sup>2</sup>	40	200
under B.E. <sup>1</sup>	NA	30	140
Alveolar Capillaries	NA	0.2	1.0

<sup>1</sup> Alpha dose equivalent for continuous exposure to the indicated <sup>222</sup>Rn concentration.

<sup>2</sup> Dose a function of deposition velocity assumed. Values are for 0.045 and 1 cm min<sup>-1</sup>.

<sup>3</sup> NA Not Applicable. Dosimetry calculations described in text.

<sup>4</sup> B.E. Bronchial epithelium. T lymphocytes can be in or directly under bronchial epithelium (see text).

FIGURE 2

